CPEB4 protein plays an essential role in cancer progression A study by researchers Ra-l M-ndez, ICREA Study Professor at the Institute for Analysis in Biomedicine and Pilar Navarro at the IMIM describes a new reprogramming mechanism for the expression of genes responsible for turning a wholesome cell into a tumor cell. In the scholarly study, published in this week’s edition of Character Medicine, the scientists have identified the proteins CPEB4 as a cellular orchestra conductor that activates a huge selection of genes connected with tumor growth.
CRI, Oncovir sign brand-new investment agreement to produce immunological stimulant Cancer Analysis Institute, Inc. , a U.S. Nonprofit organization founded in 1953 to advance the science of tumor immunology and foster the discovery and advancement of new cancers immunotherapies, announced today that its Cancer Vaccine Acceleration Fund , a joint initiative with the Ludwig Institute for Tumor Research , has completed a new investment agreement with Oncovir, Inc., a biotechnology company located in Washington, D.C., to enable the production of the immunological stimulant Hiltonol – . CVAF support is a critical factor enabling the manufacture of enough high-grade Hiltonol – for medical testing not merely in cancer vaccines, but also for many other diseases that it holds promise also, says Andres M.